Adagio Medical Advances VT Ablation Tech with Favorable Trial Data, Board Addition — Adagio Medical Holdings, Inc.

Event summary

Completed enrollment of 209-patient FULCRUM-VT Pivotal FDA IDE trial in 11 months, with preliminary results showing 97% acute effectiveness.
Raised $19 million in private placement, with potential for up to $31 million in additional gross proceeds.
Appointed Sean Salmon, former Medtronic executive, to the Board of Directors.
Strengthened executive leadership with appointments of Marie-Claude Jacques and Antwan Gipson in key roles.
Reported net loss of $25.1 million for full year 2025, down from $75.0 million in 2024.

The big picture

Adagio Medical is positioning itself as a leader in catheter ablation technologies for cardiac arrhythmias, with a focus on its proprietary ULTA technology. The completion of the FULCRUM-VT trial and the addition of experienced executives signal a strategic push towards commercialization and regulatory approval. The company's ability to secure additional funding and manage its financial position will be critical in sustaining its growth trajectory.

What we're watching

Regulatory Approval: Whether the FULCRUM-VT trial results will support FDA premarket approval for the vCLAS System.
Commercialization Readiness: The pace at which Adagio can prepare for commercialization following potential FDA approval.
Financial Sustainability: How Adagio will manage its cash position and potential additional funding needs.